公开(公告)号：US20180153938A1

公开(公告)日：2018-06-07

申请号：US15571593

申请日：2015-11-24

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： Armand KEATING ,  Brent Allen WILLIAMS ,  Xing-Hua WANG

IPC: A61K35/17 ,  A61K39/395 ,  C12N5/0783 ,  A61P35/02

CPC classification number: A61K35/17 ,  A61K39/395 ,  A61K2039/505 ,  A61P35/02 ,  C07K16/2803 ,  C07K2317/732 ,  C12N5/0646

Abstract: Treatment of cancer in a patient comprises administering to the patient an effective amount of an antibody and an effective amount of NK cells, wherein the antibody binds an antigen on the surface of the NK cells and the antibody binds to an Fc receptor on a cell of the cancer. Anticancer activity is via resultant killing action of the NK cell on the cancer cell now binding the antibody via R-ADCC.

公开(公告)号：US20210161957A1

公开(公告)日：2021-06-03

申请号：US16931332

申请日：2020-07-16

Applicant: University Health Network

Inventor： Armand KEATING ,  Brent Allen WILLIAMS ,  Xing-Hua WANG

IPC: A61K35/17 ,  C07K16/28 ,  A61P35/02 ,  A61K39/395 ,  C12N5/0783

Abstract: Treatment of cancer in a patient comprises administering to the patient an effective amount of an antibody and an effective amount of NK cells, wherein the antibody binds an antigen on the surface of the NK cells and the antibody binds to an Fc receptor on a cell of the cancer. Anticancer activity is via resultant killing action of the NK cell on the cancer cell now binding the antibody via R-ADCC.